Matinas BioPharma Hldgs Analyst Ratings
Matinas BioPharma Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 412.38% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 08/13/2020 | 497.78% | Aegis Capital | $3.25 → $3.5 | Maintains | Buy |
| 01/27/2020 | 412.38% | Piper Sandler | → $3 | Initiates Coverage On | → Overweight |
| 01/24/2020 | 412.38% | SunTrust Robinson Humphrey | → $3 | Initiates Coverage On | → Buy |
| 06/26/2019 | 583.18% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 05/17/2019 | 753.97% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 02/11/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 11/13/2018 | 753.97% | Maxim Group | $2 → $5 | Maintains | Buy |
| 08/13/2018 | 241.59% | Maxim Group | $3 → $2 | Maintains | Buy |
| 07/10/2018 | 412.38% | Maxim Group | $4 → $3 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年1月31日 | 412.38% | HC Wainwright公司 | →$3 | 重申 | →购买 |
| 2020年08月13日 | 497.78% | 宙斯盾资本 | $3.25→$3.5 | 维护 | 买 |
| 2020/01/27 | 412.38% | 派珀·桑德勒 | →$3 | 开始承保 | →超重 |
| 1/24/2020 | 412.38% | SunTrust Robinson Humphrey | →$3 | 开始承保 | →购买 |
| 2019年06月26日 | 583.18% | HC Wainwright公司 | →$4 | 开始承保 | →购买 |
| 2019年05月17日 | 753.97% | BTIG | →$5 | 开始承保 | →购买 |
| 2019年02月11日 | - | 罗斯资本 | 开始承保 | →购买 | |
| 2018年11月13日 | 753.97% | Maxim集团 | $2→$5 | 维护 | 买 |
| 2018年08月13日 | 241.59% | Maxim集团 | $3→$2 | 维护 | 买 |
| 2018年07月10日 | 412.38% | Maxim集团 | $4→$3 | 维护 | 买 |
What is the target price for Matinas BioPharma Hldgs (MTNB)?
Matinas BioPharma Hldgs(MTNB)的目标价格是多少？
The latest price target for Matinas BioPharma Hldgs (AMEX: MTNB) was reported by HC Wainwright & Co. on January 31, 2023. The analyst firm set a price target for $3.00 expecting MTNB to rise to within 12 months (a possible 412.38% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年1月31日报道了Matinas BioPharma Hldgs(美国证券交易所代码：MTNB)的最新目标价。这家分析公司将目标价定为3美元，预计MTNB将在12个月内上涨至(可能上涨412.38%)。1家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Matinas BioPharma Hldgs (MTNB)?
Matinas BioPharma Hldgs(MTNB)的最新分析师评级是多少？
The latest analyst rating for Matinas BioPharma Hldgs (AMEX: MTNB) was provided by HC Wainwright & Co., and Matinas BioPharma Hldgs reiterated their buy rating.
Matinas BioPharma Hldgs(美国证券交易所代码：MTNB)的最新分析师评级由HC Wainwright&Co.提供，Matinas BioPharma Hldgs重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Matinas BioPharma Hldgs (MTNB)?
Matinas BioPharma Hldgs(MTNB)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Matinas BioPharma Hldgs的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Matinas BioPharma Hldgs的最后一次评级是在2023年1月31日提交的，所以你应该预计下一次评级将在2024年1月31日左右的某个时候提供。
Is the Analyst Rating Matinas BioPharma Hldgs (MTNB) correct?
分析师对Matinas BioPharma Hldgs(MTNB)的评级正确吗？
While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a reiterated with a price target of $0.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.59, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Matinas BioPharma Hldgs(MTNB)评级重申，目标价在0.00美元至3.00美元之间。Matinas BioPharma Hldgs(MTNB)目前的交易价格为0.59美元，在分析师的预测范围内。